Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for irritable bowel syndrome
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Eluxadoline (Mu Delta) for irritablebowelsyndrome (diarrhoea-predominant) ? first line Eluxadoline (Mu Delta) for irritablebowelsyndrome (diarrhoea-predominant) – first line Eluxadoline (Mu Delta) for irritablebowelsyndrome (diarrhoea-predominant) – first line NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC (...) . Eluxadoline (Mu Delta) for irritablebowelsyndrome (diarrhoea-predominant) – first line. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Diarrhea; Gastrointestinal Agentss; IrritableBowelSyndrome; Receptors, Opioid, delta; Receptors, Opioid, mu Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR
A Randomized, Controlled, Crossover Study of Sacral Nerve Stimulation for IrritableBowelSyndrome To investigate whether sacral nerve stimulation reduces irritablebowelsyndrome (IBS)-specific symptoms by a randomized, controlled, crossover study.IBS affects 3% to 22% of the population worldwide, but most patients continue to have symptoms despite treatment.Patients included from our tertiary center had diarrhea-predominant or mixed IBS, with a minimum baseline IBS symptom score (...) (Gastrointestinal Syndrome Rating Scale-IBS questionnaire) of 40 points reduced by a minimum of 30% during the percutaneous nerve evaluation before permanent implantation. Patients were randomized (1:1) to have the stimulator ON or OFF for 1 month and then the opposite for another month. Investigators and patients were not informed of the setting. IBS-specific symptoms and quality of life were assessed through bowel diaries and validated questionnaires. Primary endpoint was the IBS-specific symptom score.Twenty
A randomised trial of ondansetron for the treatment of irritablebowelsyndrome with diarrhoea Irritablebowelsyndrome with diarrhoea (IBS-D) is particularly debilitating due to urgency and episodic incontinence. Some 5-hydroxytryptamine 3 (5-HT3) receptor antagonists (5-HT3RAs) have proven effective but have serious side effects. Ondansetron, also a 5-HT3RA, has been widely used as an antiemetic with an excellent safety record for over two decades. Our aim was to assess its effectiveness
Linaclotide (Constella) - irritablebowelsyndrome All Wales Medicines Strategy Group (AWMSG) - linaclotide (Constella) | | Appraisal information Search and reports linaclotide (Constella®) Reference No. 948 Publication date: 27/02/2014 Last review date: 10/03/2017 Appraisal information linaclotide (Constella®) 290 micrograms capsule Company: Allergan Ltd BNF category: Gastro-intestinal system NMG meeting date: 27/11/2013 AWMSG meeting date: 15/01/2014 Submission Type: Full Submission Status (...) : Recommended with restrictions Advice No: 0314 Ratification by Welsh Government: 26/02/2014 Current Progress Submission received NMG meeting AWMSG meeting Ratification by Welsh Government AWMSG advice Linaclotide (Constella®) is recommended as an option for restricted use within NHS Wales. Linaclotide (Constella®) should be restricted for use in the following subpopulation within its licensed indication for the symptomatic treatment of moderate to severe irritablebowelsyndrome (IBS) with constipation
Probiotics for antibiotic-associated diarrhea, clostridium difficile infection and irritablebowelsyndrome: a review of clinical evidence and safety Probiotics for antibiotic-associated diarrhea, clostridium difficile infection and irritablebowelsyndrome: a review of clinical evidence and safety Probiotics for antibiotic-associated diarrhea, clostridium difficile infection and irritablebowelsyndrome: a review of clinical evidence and safety CADTH Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Probiotics for antibiotic-associated diarrhea, clostridium difficile infection and irritablebowelsyndrome: a review of clinical evidence and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013 Authors' conclusions A large body
Low-FODMAP diets : irritablebowelsyndrome (IBS) RACGP - Low-FODMAP diets for irritablebowelsyndrome (IBS) Search Become a student member today for free and be part of the RACGP community A career in general practice Starting the GP journey Enrolments for the 2019.1 OSCE FRACGP exams closing 29 March 2019 Fellowship FRACGP exams Research Practice Experience Program is a self-directed education program designed to support non vocationally registered doctors on their pathway to RACGP (...) Releases 2016 Media Releases 2015 Media Releases 2014 Media Releases 2013 Media Releases 2012 Media Releases Search Low-FODMAP diets for irritablebowelsyndrome (IBS) Low-FODMAP diets for irritablebowelsyndrome (IBS) Intervention A nutritionally balanced diet that is low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) for adults with irritablebowelsyndrome (IBS). Basis of the intervention FODMAPs are fermentable, osmotically active, short-chain carbohydrates
Pharmacological Management of IrritableBowelSyndrome AGA SECTION American Gastroenterological Association Institute Guideline on the Pharmacological Management of IrritableBowelSyndrome David S. Weinberg, 1 Walter Smalley, 2 Joel J. Heidelbaugh, 3 and Shahnaz Sultan 4,5 1 Fox Chase Cancer Center, Philadelphia, Pennsylvania; 2 VA Tennessee Valley Healthcare System, Vanderbilt University, Nashville, Tennessee; 3 University of Michigan Ann Arbor, Michigan; 4 Department of Veterans Affairs (...) Medical Center, Gastroenterology Section, North Florida/South Georgia Veterans Health System, Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, Gainesville, Florida; and 5 Minneapolis Veterans Affairs Health System, University of Minnesota, Minneapolis, Minnesota T his documentpresentstheof?cialrecommendations of the American Gastroenterological Association (AGA)ontheuseofpharmacologicalagentsforthetreatment of irritablebowelsyndrome (IBS) in adults. The guideline
Gut-directed hypnotherapy for functional abdominal pain or irritablebowelsyndrome in children: a systematic review Gut directed hypnotherapy (HT) is shown to be effective in adult functional abdominal pain (FAP) and irritablebowelsyndrome (IBS) patients. We performed a systematic review to assess efficacy of HT in paediatric FAP/IBS patients.We searched Medline, Embase, PsychINFO, Cumulative Index to Nursing and Allied Health Literature databases and Cochrane Central Register of Controlled
Long-Term Success of GUT-Directed Group Hypnosis for Patients With Refractory IrritableBowelSyndrome: A Randomized Controlled Trial Gut-directed hypnotherapy (GHT) in individual sessions is highly effective in the treatment of irritablebowelsyndrome (IBS). This study aimed to assess the long-term effect of GHT in group sessions for refractory IBS.A total of 164 patients with IBS (Rome-III-criteria) were screened, and 100 refractory to usual treatment were randomized 1:1 either to supportive
The Efficacy of a Diet Low in Fermentable Sugars in the Reduction of Symptoms for Patients with IrritableBowelSyndrome "The Efficacy of a Diet Low in Fermentable Sugars in the Reduction of S" by Odessa Steigleder < > > > > > Title Author Date of Graduation Summer 8-10-2013 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background : Irritablebowelsyndrome (IBS) is a common disorder, affecting 7-10% of the worldwide population (...) , and Google Scholar with use of keywords “FODMAP diet” and “irritablebowelsyndrome.” Further review of bibliographies was completed for any other relevant resources. Articles were then assessed for quality using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE). Results : After reviewing for relevancy, three articles met inclusion criteria. These articles included three randomized control trials. A double-blinded, randomized, placebo-controlled trial with 26 participants
IrritablebowelsyndromeIrritablebowelsyndrome - NICE CKS Clinical Knowledge Summaries Share Irritablebowelsyndrome: Summary Irritablebowelsyndrome (IBS) is a chronic, relapsing, and often lifelong disorder of the lower gastrointestinal tract, with no discernible structural or biochemical cause. Typical clinical features are abdominal pain: Associated with a change in stool form and/or frequency. Which may be related to defaecation, and there may be associated bloating. The exact (...) . If there is no alternative explanation for ongoing symptoms, specialist referral may be appropriate to: A gastroenterologist for further investigation. A dietitian for specialist advice on single food avoidance and exclusion diets. Mental health services for psychological support and intervention. Have I got the right topic? Have I got the right topic? From age 18 years onwards. This CKS topic covers the management of irritablebowelsyndrome in adults in primary care. There are separate CKS topics
Irritablebowelsyndrome with constipation in adults: linaclotide Irritablebowelsyndrome with constipation in Irritablebowelsyndrome with constipation in adults: linaclotide adults: linaclotide Evidence summary Published: 9 April 2013 nice.org.uk/guidance/esnm16 pathways Ov Overview erview The content of this evidence summary was up-to-date in April 2013. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up- to-date (...) information. Key points from the evidence Linaclotide (Constella) is a first-in-class, oral, once-daily guanylate cyclase-C receptor agonist (GCCA), licensed for the symptomatic treatment of moderate-to-severe irritablebowelsyndrome with constipation (IBS-C) in adults. It received a European marketing authorisation in November 2012 and is expected to be launched during the first half of 2013. Linaclotide has been evaluated in 2 double-blind, randomised, placebo-controlled trials of patients with IBS-C
Evaluation of harm in the pharmacotherapy of irritablebowelsyndrome Evaluation of harm in the pharmacotherapy of irritablebowelsyndrome Evaluation of harm in the pharmacotherapy of irritablebowelsyndrome Shah E, Kim S, Chong K, Lembo A, Pimentel M CRD summary Tricyclic antidepressants and alosetron were associated with significant numbers needed to harm, compared with rifaximin, for diarrhoea. Selective serotonin re-uptake inhibitors and lubiprostone seemed to be safe, for constipation (...) . The authors' conclusions reflected the evidence presented, but lack of quality assessment, different trial lengths, and small samples in some trials mean that the reliability of the results is unclear. Authors' objectives To compare the number needed to harm for drug interventions for patients with irritablebowelsyndrome. Searching MEDLINE (1950 to April 2011), EMBASE (1980 to April 2011) and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched, without language restrictions
A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in IrritableBowelSyndrome With Constipation Linaclotide is a minimally absorbed guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide in patients with irritablebowelsyndrome with constipation (IBS-C).This phase 3, double-blind, parallel-group, placebo-controlled trial randomized IBS-C patients (...) to placebo or 290 μ g oral linaclotide once daily in a 12-week treatment period, followed by a 4-week randomized withdrawal (RW) period. There were four primary end points, the Food and Drug Administration ’ s (FDA ’ s) primary end point for IBS-C (responder: improvement of ≥ 30 % in average daily worst abdominal pain score and increase by ≥ 1 complete spontaneous bowel movement (CSBM) from baseline (same week) for at least 50 % of weeks assessed) and three other primary end points, based on improvements
Linaclotide for IrritableBowelSyndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety Linaclotide is a minimally absorbed peptide guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide treatment in patients with irritablebowelsyndrome with constipation (IBS-C) over 26 weeks.This phase 3, double-blind, parallel-group, placebo-controlled trial randomized IBS-C patients (...) to placebo or 290 μg of oral linaclotide once daily for a 26-week treatment period. The primary and the secondary efficacy assessments were evaluated over the first 12 weeks of treatment. Primary end points included the Food and Drug Administration's (FDA's) end point for IBS-C (responder: a patient who reported (i) improvement of ≥ 30 % from baseline in average daily worst abdominal pain score and (ii) increase of ≥ 1 complete spontaneous bowel movement (CSBM) from baseline, both in the same week
Mindfulness meditation for women with irritablebowelsyndrome--evidence of benefit from a randomised controlled trial. 22531145 2012 09 24 2012 07 06 1468-9618 15 3 2012 Jul Evidence-based nursing Evid Based Nurs Mindfulness meditation for women with irritablebowelsyndrome--evidence of benefit from a randomised controlled trial. 80-1 10.1136/ebnurs-2012-100488 Kearney David J DJ Department of Medicine, VA Puget Sound Health Care System, Seattle, Washington 98108, USA. kearney
Hydrogen breath test for irritablebowelsyndrome Hydrogen breath test for irritablebowelsyndrome Hydrogen breath test for irritablebowelsyndrome Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hydrogen breath test for irritablebowelsyndrome. Lansdale: HAYES, Inc.. Directory Publication. 2012 Authors' conclusions The hydrogen breath test (HBT) involves (...) obtaining breath samples before and at timed intervals after ingesting a carbohydrate substrate and analyzing these samples for hydrogen (H2) content. Intestinal bacteria ferment the carbohydrate, producing the only source of bodily H2, which is expelled in the breath. The pattern and degree of expelled H2 may indicate the presence of particular gastrointestinal (GI) disorders. Irritablebowelsyndrome (IBS) is a chronic GI disorder that is diagnosed only by symptoms but shares symptoms with other GI
Should I Consider Antibiotics in My Patient with IrritableBowelSyndrome? Should I Consider Antibiotics in My Patient with IrritableBowelSyndrome? – Clinical Correlations Search Should I Consider Antibiotics in My Patient with IrritableBowelSyndrome? July 26, 2012 6 min read By Jason Chalifoux Faculty Peer Review The story of a patient with multiple office visits due to uncontrolled abdominal pain, bloating and diarrhea/constipation is common among primary care doctors (...) and gastroenterologists. The workup is often extensive and rules out many etiologies. After discovering no metabolic, inflammatory, or anatomic pathology, physicians use the Rome III criteria to diagnose irritablebowelsyndrome (IBS). IBS is a functional bowel disorder that is diagnosed by symptoms of recurrent abdominal pain or discomfort for at least 3 days per month in the last 3 months and associated with 2 or more of the following: 1) improvement with defecation, 2) onset associated with a change in frequency
Evaluation of harm in the pharmacotherapy of irritablebowelsyndrome Current treatment options for irritablebowelsyndrome are limited and often poorly studied. A select few drugs have been studied in irritablebowelsyndrome, and the number needed to treat is frequently used to assess the relative efficacy of these treatments. However, side effects are an important consideration in the clinical decision on which particular treatment to use. This study examines trials of subjects (...) with irritablebowelsyndrome with diarrhea and constipation who are receiving a drug intervention deemed of merit by the American College of Gastroenterology task force and compares these therapies to examine the number needed to harm using a systematic review and meta-analysis approach.Potential studies of irritablebowelsyndrome treatments were identified through a search of MEDLINE (1950 to April 2011), EMBASE (1980 to April 2011), the Cochrane central register of controlled trials, and the bibliography
The efficacy and safety of rifaximin for the irritablebowelsyndrome: a systematic review and meta-analysis Irritablebowelsyndrome (IBS) affects 10-15% of the population, and treatment options are limited. Rifaximin is a minimally absorbed antibiotic that has shown efficacy in IBS patients. The objective of our study was to perform a meta-analysis and systematic review of available randomized, placebo controlled trials evaluating the efficacy and tolerability of rifaximin in patients